特一药业集团股份有限公司 董事会审计委员会对会计师事务所 2024 年度履职情况评估 及履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准则》 《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上市公司自律监 管指引第 1 号——主板上市公司规范运作》和特一药业集团股份有限公司（以下简称"公 司"）《公司章程》《董事会审计委员会工作细则》等规定和要求，董事会审计委员会 对会计师事务所 2024 年度履职评估及履行监督职责的情况汇报如下： 一、2024 年度年审会计师事务所基本情况 （一）会计师事务所基本情况 大信会计师事务所（特殊普通合伙）（以下简称"大信会计师事务所"）始创于 1985 年，2012 年 3 月按照国家财政部等有关要求转制为特殊普通合伙制，是我国最早从事 证券业务的会计师事务所以及首批获得 H 股企业审计资格的事务所之一，注册地址为北 京市海淀区知春路 1 号 22 层 2206。首席合伙人为谢泽敏。截至 2024 年 12 月 31 日， 大信会计师事务所从业人员总数 3,957 人，其中合伙人 175 人，注册会计师 1,031 人。 ...

特一药业集团股份有限公司 2024 年度财务决算报告 一、2024 年度公司财务报表的审计情况 1、公司2024年度财务报表已经大信会计师事务所（特殊普通合伙）审计，出具了 大信审字[2025]第5-00155号标准无保留意见的审计报告。会计师的审计意见是：贵公 司的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了特一药业2024 年12月31日的合并及母公司财务状况以及2024年度的合并及母公司经营成果和现金流 量。 | | 2024 年 | 2023 年 | | 本年比上年增 减 | 2022 年 | | | --- | --- | --- | --- | --- | --- | --- | | | | 调整前 | 调整后 | 调整后 | 调整前 | 调整后 | | 营业收入（元） | 687,785,167. | 1,067,212,11 | 1,067,212,11 | -35.55% | 886,570,938. | 886,570,938. | | | 66 | 0.88 | 0.88 | | 60 | 60 | | 归属于上市公 | 20,495,003.3 | 253,175,78 ...

特一药业集团股份有限公司 2024 年度董事会工作报告 2024 年，公司董事会依照《公司法》《证券法》《深圳证券交易所股票上市规则》《公 司章程》等有关法律法规及公司相关制度的规定，严格依法履行董事会的职责，本着对 全体股东负责的态度，恪尽职守、积极有效地行使职权，认真贯彻落实股东会的各项决 议，勤勉尽责地开展董事会各项工作，切实维护公司和全体股东的合法权益，保障了公 司的良好运作和可持续发展。 一、报告期公司经营情况回顾 2024 年，公司围绕"打基础、利长远"进行营销组织变革，对原有的组织架构和营 销渠道进行优化和调整，在药店销售方面逐步由经销商模式调整为自营+推广服务商的 混合模式。由于营销组织变革和营销模式的调整，涉及到销售渠道的衔接和药店销售业 务的交接，在这个过程中，为了保证变革的顺利推进，公司减少了核心产品止咳宝片的 发货，导致毛利较高的止咳宝片销售收入同比降幅较大。同时，为了进一步提高特一品 牌的市场知名度和美誉度，公司在减少止咳宝片产品发货的同时，加大对品牌的宣传力 度，当期销售费用占比较高。这些主要导致了公司 2024 年业绩下降幅度较大。 2024 年度，公司实现营业收入 68,778 ...

股票代码：002728 股票简称：特一药业 公告编号：2025-026 特一药业集团股份有限公司 关于召开 2024 年年度股东会的通知 根据《公司法》和《公司章程》的规定，公司于 2025 年 4 月 25 日召开第五届董事 会第三十次会议，现决定于 2025 年 5 月 28 日下午 2:30 在公司会议室召开 2024 年年度 股东会（以下简称"本次股东会"），现就召开本次股东会的相关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2024 年年度股东会 2、股东会召集人：公司董事会 3、会议召开的合法、合规性：本次股东会的召开符合有关法律、法规和《公司章程》 的规定。 4、 会议时间：2025 年 5 月 28 日下午 2:30 （1）现场会议召开时间：2025 年 5 月 28 日下午 2:30； （2）网络投票时间：2025 年 5 月 28 日，其中，通过深圳证券交易所交易系统进行 网络投票的具体时间为 2025 年 5 月 28 日 9:15—9:25，9:30—11:30 和 13:00—15:00； 通过深圳证券交易所互联网投票系统进行网络投票的具体时间为 2025 年 5 月 2 ...

关于第五届监事会第二十六次会议决议的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特一药业集团股份有限公司（以下简称"公司"）第五届监事会第二十六次会议于 2025 年 4 月 25 日 8:00 在公司会议室召开，会议应出席监事 3 名，实际出席监事 3 名， 均为现场出席。会议的召集、召开符合《公司法》和《公司章程》规定。 会议由公司监事会主席张名坚先生主持。与会监事审议了有关议案，一致通过以下 决议： 1、审议通过议案一《2024 年度监事会工作报告》 详见同日刊登在巨潮资讯网上的《2024 年度监事会工作报告》。 （表决结果：同意票 3 票，反对票 0 票，弃权票 0 票。） 本议案尚需提交股东会审议。 2、审议通过议案二《关于 2024 年度财务决算报告的议案》 股票代码：002728 股票简称：特一药业 公告编号：2025-020 特一药业集团股份有限公司 详见同日刊登在巨潮资讯网上的《2024 年度财务决算报告》。 （表决结果：同意票 3 票，反对票 0 票，弃权票 0 票。） 本议案尚需提交股东会审议。 3、审议通过议案三《关于 202 ...

监事会 根据《公司法》《证券法》《上市公司治理准则》《深圳证券交易所上市公司自律 监管指引第 1 号——主板上市公司规范运作》，结合《企业内部控制基本规范》及其配 套指引的规定，公司监事会对《2024 年度内部控制自我评价报告》进行了审核，意见如 下： 特一药业集团股份有限公司 监事会对公司内部控制评价报告的意见 特一药业集团股份有限公司 公司根据《公司法》等相关法律、法规要求，结合公司生产经营和管理实际情况， 已建立了较为完整、合理、有效的内部控制体系，并持续完善相关制度和流程，符合国 家相关法律法规要求，能够适应公司经营管理和发展的实际需要，并能得到有效执行。 内部控制体系的建立对公司经营管理的各环节，起到了较好的风险防范和控制作用，保 护了公司资产的安全完整，保证了公司各项业务活动的有序、有效开展，维护了公司及 股东的利益。公司《2024 年度内部控制自我评价报告》真实、客观地反映了公司内部控 制制度的建设及运行情况。监事会对公司《2024 年度内部控制自我评价报告》无异议。 2025 年 4 月 26 日 ...

股票代码：002728 股票简称：特一药业 公告编号：2025-019 特一药业集团股份有限公司 特一药业集团股份有限公司（以下简称"公司"）第五届董事会第三十次会议于 2025 年 4 月 25 日 9:00 在公司会议室采用现场及通讯方式召开，会议通知于 2025 年 4 月 15 日以邮件或书面等形式发出，本次会议应出席董事 6 名，实际出席 6 名（其中许 松青、卢北京、赵晓波、赖瀚琪以通讯表决方式出席会议）。公司监事及高级管理人员 列席了本次会议。会议的召集、召开符合《公司法》和《公司章程》的相关规定。 二、董事会会议审议情况 会议由董事长许丹青主持，全体董事经过审议，以现场及通讯方式进行表决，通过 了如下决议： 1、审议通过《2024 年度董事会工作报告》 详见同日刊登在巨潮资讯网上的《2024 年度董事会工作报告》。 （表决结果：同意票 6 票，反对票 0 票，弃权票 0 票。） 本议案尚需提交股东会审议。 2、审议通过《2024 年度总经理工作报告》 （表决结果：同意票 6 票，反对票 0 票，弃权票 0 票。） 关于第五届董事会第三十次会议决议的公告 本公司及董事会全体成员保证信息披露的内容 ...

股票代码：002728 股票简称：特一药业 公告编号：2025-021 特一药业集团股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、审议程序 特一药业集团股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第五届 董事会第三十次会议和第五届监事会第二十六次会议，审议通过了《关于 2024 年度利 润分配预案的议案》，本议案尚需提交公司 2024 年年度股东会审议。 二、利润分配预案的基本情况 （一）本次利润分配预案的基本内容 1、分配基准：2024 年度 额为 118,879,262.34 元，占本年度净利润的 580.04%。 （二）在利润分配预案公告后至实施前，如公司享有利润分配权的总股本由于股权 激励行权、股份回购等原因发生变化的，按照分配比例不变的原则，相应调整分红总额， 具体金额以实际派发情况为准（注：公司通过回购专户持有的本公司股份，不享有参与 利润分配的权利）。 三、现金分红预案的具体情况 | 项目 | 2024 年度 | 2023 年度 | 2022 年度 | | -- ...

Financial Performance - The company's operating revenue for 2024 was ¥687,785,167, representing a decrease of 35.55% compared to ¥1,067,212,110 in 2023[19] - The net profit attributable to shareholders for 2024 was ¥20,495,003.39, a significant decline of 91.90% from ¥253,175,789.62 in the previous year[19] - The net cash flow from operating activities was negative at -¥22,549,753.56, down 111.36% from ¥198,557,705 in 2023[19] - Basic earnings per share for 2024 dropped to ¥0.04, a decrease of 92.73% compared to ¥0.77 in 2023[19] - Total assets at the end of 2024 were ¥2,400,875,824, reflecting a decrease of 4.45% from ¥2,512,636,670 in 2023[20] - The net assets attributable to shareholders decreased by 12.22% to ¥1,764,933,238 at the end of 2024 from ¥2,010,681,910 in 2023[20] - The company reported a weighted average return on equity of 1.10% for 2024, down from 16.57% in 2023, indicating a significant decline in profitability[19] Dividend Distribution - The company plans to distribute a cash dividend of ¥0.5 per 10 shares to all shareholders, with no stock dividends issued[3] - The proposed cash dividend distribution is RMB 0.50 per 10 shares (including tax), with a total cash dividend amounting to RMB 25,029,009.70 (including tax)[169] - The total distributable profit at the end of the reporting period is RMB 353,494,039.54, with the cash dividend amount representing 100% of the total profit distribution[166] - The company has not proposed any stock dividends or capital reserve transfers in the current profit distribution plan[168] Market Position and Strategy - The company has a strong market position in traditional Chinese medicine, with its core product, the cough remedy, ranked among the top ten brands in its category[33] - Recent government policies are expected to provide significant opportunities for the development of traditional Chinese medicine, enhancing the industry's growth potential[34] - The company is focusing on enhancing product quality and marketing strategies to improve its competitive edge in the market[33] - The company is actively exploring innovative development paths to strengthen its competitiveness in the innovative drug sector[30] - The company aims to enhance brand awareness and reputation while reducing shipments of Cough Relief Tablets, resulting in higher sales expenses[43] Research and Development - The company holds 35 invention patents, 23 design patents, and 8 utility model patents as of the end of the reporting period[41] - The company is advancing several R&D projects aimed at improving product competitiveness and market share, including consistency evaluations for various pharmaceutical products[65] - The total R&D investment amounted to 47,347,279.88 in 2024, representing 6.88% of operating revenue, an increase of 1.90% from 2023[67] - The company is focusing on the innovation and development of traditional Chinese medicine, aligning with national policies to promote the industry, and plans to leverage its existing product lines for market expansion[104] Operational Challenges - The company has indicated potential risks in its future operations, which investors should be aware of[3] - The company has not made any changes to its main business since its listing[19] - The company has seen a significant increase in shareholding for Xu Songqing, with a total of 40,572,000 shares after the rights distribution[133] - The lengthy and costly drug development process presents risks, but the company is committed to improving its R&D capabilities and collaborating with external research institutions to advance high-quality generic drug projects[119] Environmental Compliance - The company holds valid pollution discharge permits for its subsidiaries, with expiration dates ranging from 2025 to 2027[190] - The company adheres to multiple environmental protection laws and industry standards, including the "Water Pollutants Discharge Standards for Traditional Chinese Medicine"[189] - The company has established a comprehensive internal control system to prevent financial misstatements and fraud[184] - The company has developed an environmental self-monitoring plan, conducting daily monitoring of pollutant emissions and engaging third-party testing agencies for regular assessments[200] Governance and Management - The company has established a robust governance structure, complying with relevant laws and regulations[126] - The company actively protects the rights of minority shareholders during shareholder meetings[126] - The company has a dedicated investor relations management system to ensure transparent communication with investors[127] - The company has a total of 901,600 shares held by the financial director after a stock option exercise[133] Employee and Talent Management - The company has implemented a training plan to foster talent development aligned with its strategic goals[157] - The company has a total of 1,341 employees, with 705 in the parent company and 636 in major subsidiaries[155] - The professional composition includes 722 production personnel, 203 sales personnel, and 290 technical personnel[155] - The management team includes experienced professionals with backgrounds in pharmaceutical technology and management[145]

Financial Performance - The company's revenue for Q1 2025 reached ¥295,133,348.45, representing a 79.29% increase compared to ¥164,611,744.46 in the same period last year[5] - Net profit attributable to shareholders was ¥31,567,273.65, a significant increase of 244.82% from ¥9,154,620.96 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥31,706,892.60, reflecting a 255.28% increase from ¥8,924,581.10 in the previous year[5] - Basic earnings per share increased to ¥0.06, a 200.00% rise from ¥0.03 in the previous year[5] - Operating profit for the current period was ¥39,868,269.15, compared to ¥11,312,896.62 in the previous period, reflecting an increase of approximately 252.5%[17] - The net profit for the current period is 31,567,273.65, compared to 9,154,620.96 in the previous period, representing a significant increase[18] Cash Flow - Operating cash flow net amount improved to ¥89,383,755.80, a 327.00% increase from -¥39,376,492.11 in the same period last year[5] - Cash inflow from operating activities totaled 335,732,874.13, compared to 167,275,775.68 in the previous period, indicating a growth of 100.5%[20] - The net cash flow from operating activities is 89,383,755.80, a turnaround from a negative cash flow of -39,376,492.11 in the previous period[20] - Cash outflow from investing activities was 159,330,790.44, compared to 66,834,461.53 in the previous period, reflecting an increase of 138.2%[21] - The net cash flow from investing activities is -68,944,379.48, worsening from -46,812,491.92 in the previous period[21] - Cash inflow from financing activities was 274,580,687.52, down from 292,915,169.80 in the previous period[22] - The net cash flow from financing activities is -143,692,283.28, compared to -78,472,431.97 in the previous period, indicating a decline[22] - The ending cash and cash equivalents balance is 179,708,816.53, down from 382,154,235.62 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,221,913,600.05, a decrease of 7.45% from ¥2,400,875,824.19 at the end of the previous year[5] - Current assets decreased from ¥950,947,063.46 to ¥777,616,074.33, a reduction of approximately 18.2%[16] - Cash and cash equivalents dropped from ¥457,414,315.11 to ¥230,161,408.15, a decrease of about 49.7%[16] - Short-term borrowings decreased significantly from ¥516,093,372.63 to ¥260,000,000.00, a reduction of approximately 49.6%[16] - The total liabilities decreased from ¥635,942,585.62 to ¥423,433,632.10, a decline of about 33.4%[16] - The company's retained earnings increased from ¥353,494,039.54 to ¥385,061,313.19, an increase of approximately 8.9%[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 63,146[10] - The largest shareholder, Xu Danqing, holds 27.31% of the shares, totaling 139,973,400 shares[10] - The top ten shareholders include both individual and institutional investors, with significant holdings by Xu family members[11] - There are no preferred shareholders reported in the current period[12] Marketing and Investment - The company reported a significant increase in sales expenses, which rose by 238.02% to ¥85,855,783.63 due to increased investment in new media advertising[9] - Brand building investment amounted to 106 million RMB during the reporting period[12] - The company is undergoing marketing organizational changes and brand marketing construction since 2024, with initial positive results[12] - The company emphasizes risk prevention and financial strategy optimization amid ongoing marketing reforms[12] - The company maintains a focus on long-term development while adapting to market changes[12] - The company warns investors to be aware of investment risks due to ongoing marketing reforms[12] Research and Development - Research and development expenses were ¥9,512,915.33, down from ¥11,100,583.43, indicating a decrease of about 13.5%[17] Other Information - The company has not undergone an audit for the first quarter report[23]